The study led to questions about whether patients would be best served by being treated at high-volume centers of excellence.

In EARLY TAVR, intervention improved outcomes over waiting in patients with class II or no indications for AVR consideration.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

The findings highlight the importance of having an EP versed in lead management on the heart valve team, one expert says.

The test of nonaerobic functioning may raise awareness that people need to work on balance and flexibility as they age.

PanEcho isn’t yet ready to be a standalone tool, researchers say, but shows promise at improving workflows and patient care.

Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

The procedures are not mutually exclusive, however, and should be considered on a patient-by-patient basis, a researcher says ...

This month: pharmacy’s growing CICU role, arrhythmias’ impact on pregnancy, Life’s Essential 8 in practice, and more.

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

The once-monthly drug is still under study but could provide added convenience and another option for patients.